Established in 1990, Raymedica®, Inc. is the Pioneer and Leader in all aspects of scientific and clinical experience with the use of Nucleus Arthroplasty™ devices. The Company is focused on the development and manufacture of spinal disc nucleus arthroplasty devices to treat degenerative disc disease (DDD) and disc herniations, both of which can cause debilitating back and leg pain.
Raymedica’s philosophy is to:
Create a total technology solution, not just a product.
Devote ourselves to solid clinical outcomes.
Expand our scientific, clinical, technological and regulatory expertise.
Collaborate closely with our Surgeon and Scientific Advisory Councils.
Raymedica’s Leadership Position
More than 3,500 patients implanted worldwide
1st nucleus replacement device to be approved for FDA IDE study
1st nucleus replacement device to receive CE-Mark
More than 9 years of clinical experience, with some of the first patients implanted in 1996 still enjoying successful clinical outcomes
More than 15 years of knowledge, research and expertise with hydrogel materials
More than 500 pre-clinical tests
Education leader with approximately 150 clinical papers and 81 posters
Largest IP portfolio with 45 patents issued and 20 pending worldwide